Antiglutamatergic drugs in the treatment of Parkinson's disease.


In the last two decades drugs targeting glutamatergic pathways have been a matter of growing interest for the treatment of a wide variety of neurologic disorders, including Parkinson’s disease (PD) (Lipton and Rosenberg, 1994). In the vertebrate brain glutamate is the main excitatory neurotransmitter and mediates neurotransmission of most excitatory… (More)
DOI: 10.1016/S0072-9752(07)84036-X


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics